South Korean medical artificial intelligence (AI) provider Lunit has raised $61m in its pre-IPO fundraising round, which was led by major global healthcare investors.

The move comes ahead of Lunit’s South Korean stock market (KOSDAQ) public offering early next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US healthcare investors Casdin Capital, HealthQuest Capital, and American Cancer Society BrightEdge joined the funding round.

Asia-based global healthcare investors NSG Ventures and Tybourne Capital Management also participated.

Healthcare growth equity firm HealthQuest Capital has invested $20m of the total amount.

In July this year, the company secured $26m investment from Guardant Health in a strategic funding round.

In total, the company has secured more than $135m in funding so far.

Lunit CEO Brandon Suh said: “It is a great pleasure to be successfully closing this round, consisting of major biotech investors. It is a result of hard work throughout the years to establish ourselves as one of the leading medical AI companies in the world.

“Our purpose of the last few investment rounds has been to find partners who would bring strategic value for our future endeavours. Through these partnerships we look forward to reinforcing our journey to conquer cancer through AI.”

Founded in 2013, the company develops AI-powered diagnostic tools for detecting cancer. It also develops biomarkers for accurate prediction and guiding the patients who respond to specific cancer treatment.

Lunit INSIGHT MMG recently received 510(k) clearance from the US Food and Drug Administration (FDA) for detecting breast cancer.

The new AI solution accurately analyses mammography images to detect lesions indicative of breast cancer.

It also generates the location information of detected breast cancer in the form of heatmaps and outlines.